Overview
- On May 4, 2026 GeneDx disclosed a $31.2–$31.3 million impairment tied to its April 2025 acquisition of Fabric Genomics, said adjusted gross margin fell from 74% to 69%, and cut full-year revenue guidance to $475–$490 million.
- The company’s May 4 disclosure triggered a severe market reaction that sent the stock down about 49% on May 5, 2026 and wiped out large investor gains.
- Several lawsuits and firm-led investigations now allege GeneDx and some executives misled investors about Fabric’s contribution, the durability of the company’s average reimbursement rate (ARR), and an adverse product-mix shift toward lower-reimbursing genome tests.
- Multiple plaintiff firms have filed or announced suits, the case Basma v. GeneDx (No. 26-cv-00880) is pending in the U.S. District Court for the District of Connecticut, and lead-plaintiff motions are due by August 3, 2026.
- If a lead plaintiff is appointed the litigation could produce discovery into when management learned of Fabric’s problems and how product mix and ARR changes affected margins, but no class has been certified and the allegations remain unproven.